Zabihi Mohsen, Hajhashemi Valiollah, Talebi Ardeshir, Minaiyan Mohsen
School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Pharmacology and Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
EXCLI J. 2017 Mar 30;16:414-425. doi: 10.17179/excli2016-727. eCollection 2017.
Anti-colitis effect of antidepressants has been demonstrated recently. Doxepin, a tricyclic antidepressant drug (TCA), with potent H, H, alpha adrenergic and muscarinic receptor blocking effects could be a good candidate for investigation for its anti-colitis activity. Moreover high prevalence of depression in patients who suffer from IBD (inflammatory bowel disease), defends this idea that adjuvant therapy with an antidepressant drug which has anti-inflammatory effect, may exert favorable effects in the control of the disease. In this study colitis was induced by acetic acid instillation into rat's colon. Doxepin was injected by intraperitoneal (10, 20, 40 mg/kg, twice daily, i.p.) or intracerebroventricular (50 and 100 microgram/rat, i.c.v.) routes to separate the mechanisms are absolutely exerted centrally or mediated both centrally and peripherally prior to induction of colitis. Dexamethasone (2 mg/kg/day, i.p.) was used as reference drug. All the treatments continued for three successive days. The effectiveness of drug was evaluated by determination of cytokines (TNFα, IL6 and IL1β) and myeloperoxidase (MPO) activity as well as macroscopic scores and histopathological parameters. Doxepin after i.p. administration was effective to reduce colitis severity through reduction in the macroscopic and microscopic colonic parameters, MPO activity and cytokines levels. Intracerebroventricular administration of the drug in contrast, did not show any significant protective effect suggesting no important central mechanisms for anti-colitis activity of doxepin. Doxepin as an ancient antidepressive drug has anti-colitis and anti-inflammatory properties which are mainly exerted peripherally so it could be introduced as a good candidate for depressed people who suffered from IBD disorders.
抗抑郁药的抗结肠炎作用最近已得到证实。多塞平是一种三环类抗抑郁药(TCA),具有强大的组胺、α肾上腺素能和毒蕈碱受体阻断作用,因其抗结肠炎活性可能是一个很好的研究对象。此外,炎症性肠病(IBD)患者中抑郁症的高患病率支持了这样一种观点,即使用具有抗炎作用的抗抑郁药进行辅助治疗可能对疾病的控制产生有利影响。在本研究中,通过向大鼠结肠内注入乙酸诱导结肠炎。多塞平通过腹腔注射(10、20、40mg/kg,每日两次,腹腔注射)或脑室内注射(50和100μg/大鼠,脑室内注射)给药,以区分其作用机制是完全在中枢发挥还是在结肠炎诱导前在中枢和外周均有介导。地塞米松(2mg/kg/天,腹腔注射)用作参考药物。所有治疗连续进行三天。通过测定细胞因子(TNFα、IL6和IL1β)和髓过氧化物酶(MPO)活性以及宏观评分和组织病理学参数来评估药物的有效性。腹腔注射多塞平可有效降低结肠炎严重程度,通过降低宏观和微观结肠参数、MPO活性和细胞因子水平来实现。相比之下,脑室内注射该药物未显示出任何显著的保护作用,表明多塞平的抗结肠炎活性没有重要的中枢机制。多塞平作为一种古老的抗抑郁药具有抗结肠炎和抗炎特性,主要在外周发挥作用,因此它可以作为患有IBD疾病的抑郁症患者的一个良好候选药物。